UnknownNot Applicable

PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas

Turkey (Türkiye)60 participantsStarted 2019-05-27

Plain-language summary

In this study, we aimed to investigate the relationship between PTEN-AKT-FOXO3 gene expression and decrease in ovarian reserve in the presence of endometrioma and other benign ovarian pathologies.

Who can participate

Age range

18 Years – 40 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1\) To be in the range of 18-40 years 2) Patients with an operation indication with \>=5 cm endometrioma 3) Patients with operation plan due to non-endometrioma ovarian pathologies Exclusion Criteria: * 1)Patients over the age of 40 2)Patients with suspected malignancy 3)Follow-up patients without indications for operation

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

PTEN AKT FOXO3 gene expression

Timeframe: 30 minutes

Trial details

NCT IDNCT04058912

SponsorUludag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-05-27

Contact for this trial

HAMZA F SEN, MD

+90 544 3939159 hamzafurkansen@yahoo.com

View on ClinicalTrials.gov More Ovarian Reserve, Endometrioma, PTEN-AKT-FOXO3 Gene Expression trials